scholarly journals S39 The Role Of Soluble Guanylate Cyclase Stimulator Bay 41-2272 On Remodelling Processes Relevant To The Pathogenesis Of Pulmonary Arterial Hypertension

Thorax ◽  
2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. A22-A23
Author(s):  
D. Shao ◽  
S. Wort
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator ◽  
Pulmonary Arterial

Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats

2021 ◽  
Vol 897 ◽  
pp. 173948
Author(s):  
Karoline Gonzaga-Costa ◽  
Alfredo Augusto Vasconcelos-Silva ◽  
Matyelle Jussára Rodrigues-Silva ◽  
Conceição da Silva Martins Rebouça ◽  
Glória Pinto Duarte ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Beneficial Effect ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator ◽  
Pulmonary Arterial

The soluble guanylate cyclase stimulator, 1-nitro-2-phenylethane, reverses monocrotaline-induced pulmonary arterial hypertension in rats

Life Sciences ◽  
2021 ◽  
Vol 275 ◽  
pp. 119334
Author(s):  
Karoline Gonzaga-Costa ◽  
Cássia Rodrigues Roque ◽  
Alfredo Augusto Vasconcelos-Silva ◽  
Hellida Larissa Sousa-Brito ◽  
Conceição Silva Martins ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Soluble Guanylate Cyclase Stimulator ◽  
Pulmonary Arterial

scholarly journals Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

2017 ◽  
Vol 8 (1) ◽  
pp. 204589321774611 ◽  
Author(s):  
Mitsushige Murata ◽  
Takashi Kawakami ◽  
Masaharu Kataoka ◽  
Takashi Kohno ◽  
Yuji Itabashi ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Contractile Function ◽  
Ventricular Contraction ◽  
Soluble Guanylate Cyclase Stimulator ◽  
Pulmonary Arterial

Riociguat is a soluble guanylate cyclase stimulator used for pulmonary hypertension (PH) treatment. We evaluated right ventricular (RV) contractile function in 27 PH patients receiving riociguat. A comparison of pre- and post-administration echocardiographic studies demonstrated significantly improved RV strain after riociguat treatment, even after adjusting for RV afterload.

scholarly journals Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension

2008 ◽  
Vol 32 (4) ◽  
pp. 881-891 ◽  
Author(s):  
R. T. Schermuly ◽  
J-P. Stasch ◽  
S. S. Pullamsetti ◽  
R. Middendorff ◽  
D. Muller ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Pulmonary Arterial ◽  
And Function

scholarly journals Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator

2018 ◽  
Vol 13 (1) ◽  
pp. 35 ◽  
Author(s):  
Hiroshi Watanabe ◽  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Pharmacological Action ◽  
Cyclic Guanosine Monophosphate ◽  
Guanosine Monophosphate ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
Pulmonary Arterial ◽  
Phosphodiesterase Type

Pulmonary arterial hypertension is a chronic and life-threatening disease that if left untreated is fatal. Current therapies include stimulating the nitric oxide–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate axis, improving the prostacyclin pathway and inhibiting the endothelin pathway. Phosphodiesterase type 5 inhibitors, such as sildenafil, and the sGC stimulator riociguat are currently used in the treatment of pulmonary arterial hypertension. This article discusses the similarities and differences between phosphodiesterase type 5 inhibitors and sGC stimulator based on pharmacological action and clinical trials, and considers which is better for the treatment of pulmonary arterial hypertension.

scholarly journals The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat

2020 ◽  
Vol 92 (9) ◽  
pp. 77-84
Author(s):  
S. E. Gratsianskaya ◽  
Z. S. Valieva ◽  
T. V. Martynyuk
Keyword(s):  
Clinical Trials ◽  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Guanylate Cyclase ◽  
Soluble Guanylate Cyclase ◽  
Chronic Thromboembolic Pulmonary Hypertension ◽  
No Production ◽  
Thromboembolic Pulmonary Hypertension ◽  
Pulmonary Arterial

Currently, treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) is focused on three signaling pathways: the NO pathway, the endothelin pathway, and the prostacyclin pathway. Riociguat is the only representative of stimulators of the soluble guanylate cyclase (sGC) class that is approved for the treatment of PAH and inoperable and persistent/recurrent CTEPH. The review presents data from clinical trials showing a positive effect of riociguat on the functional and hemodynamic profile of patients with PAH and CTEPH. In recent years there has been much discussion about the possibility of optimizing therapy by switching to drugs that affect a single pathogenesis target. Thus, sGC stimulants have obvious advantages over phosphodiesterase type 5 (PDE-5) inhibitors, including the ability of riociguat to exert pharmacological effects (due to a NO-independent mechanism of action) even in conditions of reduced NO production. Switching from PDE-5 to riociguat may be safe and appropriate, according to clinical trials presented in the review. In accordance with the guidelines for the diagnosis and treatment of pulmonary hypertension of the Eurasian Association of cardiologists from 2019, this strategy is approved when PDE5 therapy is ineffective in patients with PAH FC III (WHO).

Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken

2016 ◽  
Vol 15 (1) ◽  
pp. 12-13
Author(s):  
Adaani E. Frost ◽  
Harrison W. Farber
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Lung Transplantation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Donor Organ ◽  
The Road ◽  
Lung Allocation Score ◽  
Pulmonary Arterial

Dramatic advances in therapy for pulmonary arterial hypertension (PAH) in the last 20 years have improved survival from a median of 2.5 years in the pretreatment era to 7.5 years currently. However, impressive as that may seem, it is important to note that a median survival of 7.5 years is equivalent to that of surgically resected non-small cell lung cancer, thus underscoring the importance of lung transplantation as a treatment option in patients with PAH. In this edition of Advances, Edelman has reviewed the pathway to transplantation for patients with PAH, detailing the recommendations for timing of referral, listing for lung transplantation, the role of the lung allocation score in allocating a donor organ, and the outcome of lung transplantation.

Sign in / Sign up

Export Citation Format

Share Document